Puig’s €1.2 Billion ISDIN Deal Buys Full Control
Puig agreed on Sept. 14 to buy Esteve’s 50% stake in ISDIN for €1.2 billion, taking the dermocosmetics company from joint ownership to full control. The consideration is unusually easy to scope: €900 million is payable at closing and €300 million is a fixed, non-interest-bearing payment due in the first quarter of 2029.
The implied valuation is more informative than the headline control premium. If the acquired half is valued proportionally, the deal implies a €2.4 billion equity value for 100% of ISDIN. Against €648 million of 2025 sales, that is about 3.7 times revenue. It is an equity-value-to-sales reference, not an enterprise-value multiple; ISDIN’s net debt or cash would be needed to convert it properly.
Puig and Esteve founded ISDIN together in 1974, so the transaction removes a governance constraint in an asset Puig already knows; it does not introduce an unfamiliar operating platform. Full ownership gives Puig all future cash flow and the ability to allocate distribution, brand investment and capital without sharing strategic authority.
The financing boundary is also explicit. Puig says it will use a combination of its own resources and financial debt and does not expect net debt to adjusted EBITDA to exceed 2.0 times. The deferred €300 million lowers the cash requirement at closing but remains a known claim in 2029.
What public materials do not provide is the acquired EBITDA, ISDIN net debt, expected synergies or an earnings-accretion bridge. Without those inputs, the 3.7-times sales reference cannot answer whether Puig is buying the remaining half cheaply or expensively relative to its own cost of capital.
The main risk is not basic integration. Puig is consolidating an asset it helped build. The return case depends on the margin and cash conversion attached to the €648 million revenue base and whether full control accelerates growth enough to justify a €1.2 billion capital commitment while staying inside the 2.0-times leverage ceiling.